Onyvax Report issue

For profit Phase 2
Founded: Bradford United Kingdom (1997)
Status: Acquired by Kael-GemVax Co., Ltd. (2008)

Organization Overview

First Clinical Trial
2000
NCT00007826
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2000

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

105ad7 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Colorectal Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1